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Abstract
Background: The aim was to examine the feasibility, acceptability and clinical utility of electronic symptom
surveillance with clinician feedback using a subset of items drawn from the Patient-Reported Outcomes version
of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a cancer treatment setting.
Methods: Danish-speaking men with castration-resistant metastatic prostate cancer receiving treatment at the
Department of Oncology, Rigshospitalet, Copenhagen between March 9, 2015 and June 8, 2015 were invited to
participate (n = 63 eligible). Participants completed the PRO-CTCAE questionnaire on tablet computers using
AmbuFlex software at each treatment visit in the outpatient clinic. In total, 22 symptomatic toxicities (41 PRO-CTCAE
items), corresponding to the symptomatic adverse-events profile associated with the regimens commonly used for
prostate cancer treatment (Docetaxel, Cabazitaxel, Abiraterone, Alpharadin), were selected. Participants’ PRO-CTCAE
responses were presented graphically to their treating oncologists via an AmbuFlex dashboard, for real-time use to
enhance the patient-clinician dialogue that occurs during the consultation prior to each treatment cycle.
Technical and clinical barriers and acceptability were evaluated through semi-structured interviews with both
patients and oncologists. Patients receiving active treatment at the end of the study period completed an
evaluation questionnaire.
Results: Fifty-four out of sixty-three (86%) eligible patients were enrolled. The PRO-CTCAE questionnaire was
completed a total of 168 times by 54 participants (median number per patient was 3, range 1–5). Eight surveys
were missed, resulting in a compliance rate of 97%. At the end of the study period, 35 patients (65%) were still
receiving active treatment and completed the evaluation questionnaire. Patients reported that their PRO-CTCAE
responses served as a communication tool. Oncologists stated that the availability of the PRO-CTCAE self-reports
during the consultation improved patient-clinician communication about side effects.
(Continued on next page)
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Conclusion: Electronic capture of symptomatic toxicities using PRO-CTCAE and the submission of self-reports to
clinicians prior to consultation were feasible among metastatic prostate cancer patients receiving chemotherapy
in an outpatient setting, and this procedure was acceptable to both patients and clinicians. Continued research,
including a cluster-randomized trial, will evaluate the effects of submitting patients’ PRO-CTCAE results to clinicians
prior to consultation on the quality of side-effects management and resultant clinical outcomes.
Keywords: PRO-CTCAE, Feasibility, Prostate cancer, Symptom surveillance, Electronic reporting
Background
Serial evaluations of treatment tolerability are an important
component of clinical monitoring of cancer therapy [1].
Tolerability determinations are based on physical examin-
ation, laboratory testing and patient self-reporting [1]. In
cancer treatment, patients are unsystematically asked about
toxicity symptoms, and the severity and presence of these
symptoms are interpreted and registered by clinicians. Fur-
ther, observational studies comparing the reporting of
symptoms via clinicians versus direct patient self-reporting
have found that clinicians’ ratings of symptom severity are
lower than those gathered using patient-reported outcome
measures [2–5]. Thus, capturing symptomatic toxicities
directly from patients using patient-reported outcome
measures may improve the accuracy of identifying and
characterizing the symptomatic adverse effects of treat-
ment [6, 7].
Now, version 4 of the National Cancer Institute’s Com-
mon Terminology Criteria for Adverse Events (CTCAE) is
the standard for reporting adverse events in cancer clinical
trials and is widely used in cancer treatment and research
settings [7]. As a companion to the CTCAE, NCI has
developed a Patient-Reported Outcome version of the
Common Terminology Criteria for Adverse Events
(PRO-CTCAE) [8].
Studies examining the feasibility of electronic patient-
reporting of symptomatic side effects of cancer treatment
have shown high acceptability of self-reporting presented
as high satisfaction with using the system [9–12], and the
patient’s experience of aided recall of symptoms helped
them feel more in control of their care [12]. Prior studies
have used hardcopy feedback reports to clinicians or a
limited number of symptom questions, as well as a variety
of software systems for patient reporting [9–14]. In this
study, we aimed to use a questionnaire covering all the
relevant symptomatic toxicities for a specific cancer treat-
ment, which is important in order to use the patient’s
reporting in the discussion of treatment tolerance and
supportive care with the oncologist. Additionally, patients’
electronic reporting of side effects prior to chemotherapy
could be displayed in real-time to both clinicians and
patients using an established patient-reported outcome
(PRO) dashboard [15]. This makes it possible to incorp-
orate patients’ experiences into the treatment-related
communication and decision-making, including side-
effects management and supportive care. We have re-
cently translated and linguistically validated a Danish
language version of the full PRO-CTCAE library [16].
In this, we report the results of a pilot study examining
the feasibility and acceptability to patients and clinicians
of collecting these data in routine clinical practice with
prostate cancer patients using PRO-CTCAE-Danish.
The purpose of this study was to examine the feasibil-
ity, acceptability and clinical utility among patients with
prostate cancer and their oncologists of systematic elec-
tronic Patient-Reported Outcome (PRO) data collection
using a subset of PRO-CTCAE items, with feedback to
clinicians in real-time during active treatment. Patients
included were castration-resistant metastatic prostate
cancer patients receiving medical oncology treatments in
an oncology clinic during a three-month study period.
This is the first study in a Danish cancer treatment setting
to investigate the feasibility of using a treatment-specific
subset of PRO-CTCAE items in a specific patient group
during active cancer treatment.
Methods
Study population
Male patients being treated for castration-resistant meta-
static prostate cancer, who were able to read, write, and
speak Danish, and who were receiving chemotherapy at
Department of Oncology, Rigshospitalet, Copenhagen
University Hospital from March 9, 2015 to June 8, 2015
were invited to participate in this study. The participants
were either initiating treatment, receiving ongoing treat-
ment or transitioning to a new treatment regimen. All
participants received oral and written information about
the study, and they gave their informed consent for
participation.
PRO-CTCAE
Items from PRO-CTCAE corresponding to the symp-
tomatic adverse-events profile associated with systemic
treatment of prostate cancer using Docetaxel, Cabazi-
taxel, Abiraterone or Alpharadin in phase III clinical,
randomized trials were used in this study [17–20]. This
resulted in 41 PRO-CTCAE items (presence, amount,
frequency, severity and/or interference with daily activities)
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reflecting 22 symptomatic toxicities that were assessed
at each clinic visit. The recall period for PRO-CTCAE
is the past seven days [8]. Conditional branching was
not employed, which means that patients were pre-
sented with all items regardless of their answers. If the
patients experienced symptoms not covered by the 41
PRO-CTCAE items, additional symptoms were soli-
cited using the free-text, write-in feature, as shown in
Table 1.
AmbuFlex
A total of 41 PRO-CTCAE items selected for this study
were encoded in the AmbuFlex software and presented
to patients on tablet computers provided at the clinic
(Fig. 1). AmbuFlex software has been developed and
used in Denmark to collect patient-reported outcomes
in a variety of chronic diseases [15, 21]. In the AmbuFlex
software, the patients’ response was available as a
graphic real-time presentation on the oncologists’ com-
puter screen. Scores for each item were reported as bars
with assorted colors, lengths and numbers (Fig. 2). Pres-
entation of graphics from previous visits alongside the
most recent response made it possible to identify change
over time. At patient visits, output was available on the
oncologist’s computer screen, which made it possible to
discuss the experienced symptoms with the patient. The
AmbuFlex software was integrated into the software sys-
tem clinicians use to order systemic anticancer treat-
ments, including chemotherapy.
Procedures for patient reporting and feedback to the
oncologist
1) Before the first treatment with chemotherapy,
patients were given a 5–10-min introduction to the
tablet computer, its functionality and how to
complete the questionnaire. The patients completed
the PRO-CTCAE questionnaire on the tablet
computer in the waiting room, using their unique
personal identification number, which all Danish
citizens are assigned at birth by the Danish Civil
Registration System (CRS) [22], as their logon to
the tablet computer (Fig. 1). Patients were asked
to complete the PRO-CTCAE questionnaire at
each treatment visit every third week in the clinic
prior to consultation with the oncologist.
Table 1 Twenty-two PRO-CTCAE symptom terms (41 items) and a write-in text box
PRO-CTCAE symptom term Presence/absence Amount Frequency Severity Interference with daily activities
Watery eyes x x
Abdominal pain x x x
Constipation x
Diarrhea x
Difficulty swallowing x
Nausea x x
Vomiting x x
Fatigue x x
General pain x x x
Decreased appetite x x
Joint pain x x x
Muscle pain x x x
Taste changes x
Numbness & tingling x x
Cough x x
Shortness of breath x x
Nosebleed x x
Hair loss x
Nail discoloration x
Nail ridging x
Rash x
Swelling x x x
Free-text, write-in feature
Other symptoms
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Throughout the entire study period, support was
provided on site by the researcher.
2) Each oncologist received a brief (5–10 min)
individual training session from the researcher
focused on how to navigate the AmbuFlex software
system, including how to locate and interpret the
graphical depictions of PRO-CTCAE scores provided
by the AmbuFlex web system.
3) The oncologists were encouraged to review the
PRO-CTCAE responses before meeting the patient
or while talking with the patient, but were not
obliged to do so as the electronic patient reporting
Fig. 1 Patients log on to the tablet computer using the unique civil registration number and complete the PRO-CTCAE questionnaire in the
waiting room
Fig. 2 Overview of patients’ reporting available at the oncologists’ computers in real-time. Items are presented as bars with different colors (for
example, red = very severe, orange = severe, yellow = moderate, light green = mild, dark green = none), lengths and numbers (1–5) for each
date of treatment visit. Note: In our study, the symptomatic toxicities were in Danish language, but are here presented in English
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was not incorporated into local guidelines. At weekly
clinic meetings, the oncologists were informed about
the progress of the study and any logistical issues
(information about the tablet computers, possible
technical issues, technical support, etc.) arising
during daily practice.
Semi-structured interviews and questionnaire data
collection
Technical feasibility, acceptability and clinical utility
were evaluated by combining individual semi-structured
interviews with patients and oncologists, and by means
of an evaluation questionnaire (developed by the re-
searchers) for patients. The three themes—technical
feasibility, acceptability and clinical utility—were selected
based on lessons learned from other studies involving
electronic patient reporting of symptoms [11, 12]. The re-
searcher registered information on participation and tech-
nical problems on a daily basis. Additionally, a log was
recorded from AmbuFlex showing the number of times
that patients’ completions of PRO-CTCAE questionnaire
were reviewed in AmbuFlex by an oncologist.
 Eight weeks into the study period, four patients
were interviewed individually by one researcher
about their experiences of completing the
PRO-CTCAE questionnaire on the tablets and
their experience of the use of their responses by
the oncologists. These semi-structured interviews
were used to identify relevant questions within the
three themes of importance to the patients. Based
on these interviews, an evaluation questionnaire
was developed. The interviews aimed to develop
the evaluation questionnaire and to present detailed
information.
 All participants receiving treatment in the clinic
during the last three weeks of the study period
were asked to complete the evaluation questionnaire
(n = 35). The evaluation questionnaire comprised 13
items regarding the patients’ experience of completing
the PRO-CTCAE questionnaire on tablets in the
clinic (information and help with technical issues,
waiting area, oncologists’ and nurses’ use of
patients’ reporting). Additionally, there were two
items on the patients’ experience of using tablets
and computer/internet in their daily life, four items
on age, occupation, highest attained education and
marital status, and a blank write-in field for other
comments. The results were summarized using
descriptive statistics.
 At the end of the study period, one researcher
conducted individual semi-structured interviews
with the five oncologists treating prostate cancer
patients in the clinic about their opinions and expe-
riences of using the patients’ self-reporting of
symptoms during the clinical encounter.
The researcher conducted the semi-structured inter-
views in accordance with interview guides (five questions
in the interview guide for patients and seven questions
in the interview guide for oncologists), focusing on the
themes technical feasibility, acceptability and clinical
utility. All interview data was analyzed for content and
summarized according to the above-mentioned themes.
The interview data is presented with quotations from
patients and oncologists. Quotations were selected to
cover both facilitators and barriers.
Results
Participation
Between March 9, 2015 and June 8, 2015, 60 out of 63
eligible patients were approached to participate in the
study and 54 enrolled, resulting in a participation rate of
90% (54/60). The median age of the participants was
69 years (range 51–88 years). The reasons for declining to
participate included fatigue (n = 3) and a lack of interest
in the study (n = 3), while three patients were not invited
due to logistical problems (for example, the researcher
was not in the clinic when the patient met for treatment).
Feasibility of in-clinic PRO-CTCAE patient reporting with
feedback to treating oncologist
The PRO-CTCAE questionnaire was completed a total
of 168 times by 54 participants (Table 2). Eight patients
received help using the screen on the tablet computer
from their spouse, other relative or the researcher. The
problem was for all patients related to sensitivity of the
touch screen. A log from AmbuFlex showed that 45 of
the 54 patients (83%) had at least one PRO-CTCAE
questionnaire reviewed by the oncologist during the
Table 2 Number of patients completing PRO-CTCAE
First PRO-CTCAE
completion
Second PRO-CTCAE
completion
Third PRO-CTCAE
completion
Fourth PRO-CTCAE
completion
Fifth PRO-CTCAE
completion
Total number of
completions and
missed completions
Number of patients
completing PRO-CTCAE
52 50 34 24 8 168
Number of patients with
missed completion
2 3 0 1 0 6
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study period. Of the 168 completions of questionnaire,
87 completions (52%) were reviewed by an oncologist.
Six patients missed one completion of the scheduled
174 responses of the PRO-CTCAE questionnaire, giving
a compliance rate of 97% (Table 2). The reasons for
missing data included late arrival to the clinic (n = 4),
difficulty logging onto the system (n = 1), and being too
ill to report (n = 1). Furthermore, during the study period,
three patients once completed the PRO-CTCAE question-
naire after their consultation with the oncologist.
Patient interviews and evaluation questionnaire
Four patients were individually interviewed, and the
themes important to patients and the patients’ contribu-
tion were incorporated into the evaluation questionnaire.
After interviewing four patients, a point of information
saturation was reached. Since the evaluation question-
naire was based on information from some of the first
patients included in the study, the questionnaire was
only available for patients in active treatment in the last
three weeks of the study period. Thirty-five patients
(100% of the patients invited to complete the evaluation
questionnaire, 65% of the study population) responded
to the evaluation questionnaire. Their median age was
69 years, and 37% had basic/high school or vocational
education as their highest attained education (Table 3).
Technical feasibility
Patients found the tablet computers easy to use. How-
ever, 23% of the patients needed help at least for the first
time they used it (Table 4). Data from AmbuFlex soft-
ware showed that the mean time for completing the
PRO-CTCAE questionnaire was 6 min and 48 s (ranging
from 3 min and 3 s to 46 min and 24 s). Six patients re-
ported technical problems (Table 4), such as the tablet
computer shutting down and having to start over or a
slow responding tablet computer and having to touch
each key more than once. Three of the six patients
reporting technical problems are part of the 23% who
needed help using the tablet computer.
Clinical utility
A total of 46% of patients perceived that the oncologist
had reviewed their self-reported data in AmbuFlex prior
to the clinical encounter, and 34% of patients reported
that their oncologist talked with them about their self-
reported symptoms during the clinic visit (Table 4). One
patient explained: “The dialogue with the oncologist is
more efficient. The questions are about relevant prob-
lems. You can see where symptoms differ from the last
treatment, such as new side effects” and another patient
explained: “First the doctor asked about my answers:
“You have stated that …”.
Acceptability
A total of 40% of patients reported more focus on side ef-
fects compared to their prior treatments in the consultation
with the oncologist after answering the PRO-CTCAE ques-
tions and 77% thought it was a useful tool when talking to
the oncologist (Table 4). Most patients (77%) stated that
the PRO-CTCAE questionnaire enabled them to provide a
complete picture of their side effects (Table 4). One patient
explained: “You are the one who knows best and feels the
side effects. You can give a more complete picture.” Another
stated: “You remember things to talk about with the doctor.”
The system also helped patients be more aware of their
symptoms, as explained by a patient: “You become more
aware of what happens to you. You get an opportunity to
follow the changes in the symptoms.”
Oncologist interviews
Technical feasibility
The five oncologists found the AmbuFlex software easy
to use and did not spend more time than usual on the
Table 3 Characteristics of patients who completed the
structured evaluation questionnaire (n = 35)
Median age (range) in years 69 (56–79)
Highest attained education n (%)
Basic or high school 4 (11)
Vocational education 9 (26)
Higher education, 2–4 years 9 (26)
Higher education, ≥ 5 years 6 (17)
Unknown 7 (20)
Employment status
Working full time 5 (14)
Working part time 1 (3)
Retired 22 (63)
Unknown 7 (20)
Marital status
Single 3 (9)
Married or cohabiting 24 (69)
Divorced or separated 5 (14)
Unknown 3 (9)
Frequency of Use of Internet/Computer
Never 1 (3)
Sometimes 6 (17)
Often 23 (66)
Missing 5 (14)
Tablet computer or smartphone at home
No 8 (23)
Yes 23 (66)
Missing 4 (11)
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consultation when using the software. However, one on-
cologist mentioned some concern about this new task:
“It is a barrier that you have to log in to another system
[AmbuFlex] if it does not substitute other tasks.” Four
out of five oncologists described the graphic presenta-
tion as clear and providing a good overview, while one
oncologist suggested adding more pictures and/or
graphs of the patients’ symptoms. As there are continu-
ously new oncologists in training in the clinic, one of the
oncologists was given the introduction to the system
after he had started using it: “I came to the department
after the project had started. I had some questions about
how to use the system.”
Clinical utility
The oncologists expressed different views on the clinical
use of the patients’ reporting of PRO-CTCAE symptoms.
Two oncologists expressed concern regarding the pa-
tients’ rating of symptoms. One oncologist explained:
“The patient’s self-reporting gives a picture of the pa-
tient’s overall condition, but the patient’s answers were
not necessarily related to the chemotherapy.” Another
expressed that “Patients rate their symptoms differently
than we [the oncologists – ed.] would do, and patients
often underestimate or overestimate the severity of their
symptoms.” In addition, positive comments were re-
ported as expressed by one oncologist: “You get a better
impression of the patient’s overall situation—symptoms
and side effects.” Patient reporting was generally seen
by oncologists as a supplement to the clinical dialogue
with the patient in the consultation. For example, one
oncologist said: “It is positive that the patients rate
themselves—sometimes we underestimate. But the dialogue
is important for specifying the [symptom and severity].”
Acceptability
The oncologists’ general experience was expressed by
one who said: “The patients are better prepared and
have thought about the symptoms they have experienced
since the last visit,” when the patients have answered the
PRO-CTCAE questionnaire on the tablet computer be-
fore the consultation. However, one oncologist stated
that patients could find it difficult to separate the
Table 4 Results from the patient evaluation questionnaire
(n = 35)
What was your experience of using the tablet computer n (%)
Very easy 24 (69)
Easy 10 (29)
Difficult/Very Difficult 1 (3)
Did you need any help to use the tablet computer
No 26 (74)
Only the first time 7 (20)
On several occasions 1 (3)
Missing 1 (3)
Did you get the help you needed (n = 8)
Yes, from relatives 5 (63)
Yes, from the researcher 7 (88)
No, I did not get the help I needed 0 (0)
Did you experience any technical problems
No 28 (80)
Yes 6 (17)
Missing 1 (3)
How did you experience your symptom reporting
was used in the clinica
The oncologist had reviewed my symptom reporting
before the consultation
16 (46)
The oncologist talked with me about my symptom
reporting
12 (34)
The nurse had reviewed my symptom reporting 4 (11)
I don’t think that neither the oncologist nor the nurse
had reviewed my symptom reporting
4 (11)
Do not know 9 (26)
The electronic PRO-CTCAE items provided a complete
picture of my symptomatic side effects
Totally agree 5 (14)
Agree 22 (63)
Neither agree nor disagree 2 (6)
Disagree/totally disagree 0 (0)
Do not know 1 (3)
Missing 5 (14)
The electronic symptom reporting is a good tool
when talking with the oncologist
Totally agree 5 (14)
Agree 22 (63)
Neither agree nor disagree 1 (3)
Disagree/totally disagree (0)
Do not know 3 (9)
Missing 4 (11)
The electronic symptom reporting results in more focus
on side effects in the consultation
Totally agree 3 (9)
Agree 11 (31)
Table 4 Results from the patient evaluation questionnaire
(n = 35) (Continued)
Neither agree nor disagree 9 (26)
Disagree/totally disagree 1 (3)
Do not know 6 (17)
Missing 5 (14)
Some questionnaires were returned without full completions
aMore than one statement could be ticked
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gradings ‘severity’ and ‘influence on daily activity’: “Too
many similar questions. But the right thing to do—for
both patients and doctors.”
Figure 3 summarizes the barriers identified during
the study period to using the patients’ reporting of
symptoms in each step of the workflow in the clinic.
The barriers were identified from the semi-structured
interviews with patients and oncologists, the patient
evaluation questionnaire and the researcher’s daily
registration during the study period.
System availability
The AmbuFlex software was continuously available, apart
from a three-minute offline period during the three
months’ study period. This offline period did not influence
the project.
Discussion
This study demonstrates that the collection of self-
reported data using PRO-CTCAE, with real-time feedback
to treating oncologists employing the AmbuFlex system, is
feasible and acceptable in routine clinical practice with
male patients undergoing treatment for prostate cancer.
Patients stated that the PRO-CTCAE items provided a
complete overview of their experienced side effects and
that it was a good communication tool. Oncologists found
the online platform easy to use and reported that patients
were better prepared for the dialogue.
The strength of the study was the sizable percentage
of patients who agreed to participate in the study and
the substantial number of completions of the PRO-
CTCAE questionnaire. The study included male patients
only, which could be a limitation. However, we find it
plausible that the results, showing good acceptability in
the group of elderly men with different social and educa-
tional backgrounds, will also be applicable to female
adults and other cancer diagnoses, as shown in other
studies [9, 11]. Further research is needed to examine
the acceptability in other groups.
In our study, the researcher was present in the clinic
during the study period, handed over the tablet com-
puter and gave instructions to patients on how to
complete the PRO-CTCAE questionnaire. Therefore, the
setup did not reflect the routine clinical workflow. If the
tested model is to be implemented in routine practice,
it will be necessary to provide additional training to
patients, oncologists, nurses and secretaries. Our study re-
sults indicate that incorporation into local guidelines, in-
cluding all the above-mentioned matters, and sufficient
information to the clinicians are important for facilitating
patients’ reporting of symptoms before consultation.
The sustainability of the tested model will depend on
local resources to cover training, however. Further, the
electronic symptom surveillance using PRO-CTCAE
has the potential to have alerts be developed, such as
for severe symptoms, missed surveys, missed review by
clinicians. Such functionalities will be included in future
studies.
We also found a high acceptance of the technical fa-
cilities, in accordance with other feasibility studies of
electronic self-reporting systems [9–12], and patient
satisfaction with using the tool when communicating
with oncologists about symptoms [23, 24]. In addition,
oncologists found the AmbuFlex system useful as a tool to
facilitate the clinical dialogue with patients. The AmbuFlex
system has been implemented in clinics treating patients
Fig. 3 Workflow and barriers for oncologists and patients in using electronic patient reporting of symptomatic toxicities
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diagnosed with afflictions such as prostate cancer, epi-
lepsy, renal failure, sleep disorders and neuromuscular
diseases and including more than 13,000 patients [21],
and the system allows for a graphic presentation of
symptoms, which may facilitate the dialogue during the
clinical encounter.
About half of the patients in our study reported that
their oncologist had reviewed the PRO data in AmbuFlex
before the consultation. The log from AmbuFlex showed
that 83% of the patients had their answers reviewed at
least once during the study period. Even though reviewing
the PRO-CTCAE questionnaires was not compulsory,
50% of the total number of completions were reviewed
during the study period. Obtaining reviews of all PRO-
CTCAE reports might be facilitated by implementing
this procedure in local guidelines.
Some oncologists reported that their own assessment
differed from patients’ self-reported symptoms. This
conforms to previous research showing discrepancies
between the clinician’s report and the patient’s self-
reporting of the same symptom [25]. Research indicates
that part of the discrepancy between clinician and patient
report of symptoms occurs because patients report about
any symptom whereas clinicians’ reports are directed
toward toxicities attributable to treatment [26]. Patient
reporting of symptoms is shown to add information to
the clinicians reporting [4]. PRO-CTCAE was devel-
oped by the US National Cancer Institute to directly in-
corporate the patients’ experience into the capture and
reporting of symptomatic adverse events in cancer clin-
ical trials [27]. Evaluation shows that patient reporting
using PRO-CTCAE may also improve the identification
of symptoms at baseline prior to trial initiation, thus
allowing for a more precise understanding of the symp-
tomatic toxicities attributable to treatment [28]. Future
studies may reveal the impact of PRO-CTCAE on side-
effect management, for example.
The US Food and Drug Administration (FDA) states
that international collaboration on PRO measures is ne-
cessary to secure a common framework for generating
and reporting patient-centered data, including symptom-
atic toxicities, from cancer clinical trials [29]. The need
for a disease-specific instrument to capture patients’
symptomatic toxicities according to the relevant therapies
has been emphasized [29]. One of the most frequently-
used questionnaires on patient-reported symptoms are the
quality of life questionnaires of the European Organisation
for Research and Treatment of Cancer (EORTC). While
health-related quality of life (HRQOL) measures capture a
broad picture of the patients’ condition, including family
and social factors, they pay less attention to specific tox-
icity symptoms relating to the individual cancer therapy.
PRO-CTCAE has been suggested as a new standard in-
strument to measure symptomatic toxicities in clinical
cancer trials, which is flexibly adaptable to different diag-
noses and therapies [29].
One challenge to introducing patient reporting of side
effects is the risk of increasing clinicians’ workloads,
which has been suggested as a potential barrier [28].
When using PRO-CTCAE feedback as additional infor-
mation from the patient, oncologists stated that they did
not spend extra time on the consultation.
Traditionally, direct patient self-reporting using patient-
reported outcome measures has not been systematically in-
corporated into toxicity reporting. PRO-CTCAE changes
this paradigm. As studies have shown high acceptance
among patients in the self-reporting of symptoms and that
technical barriers can be overcome, the main remaining
barrier is to engage clinicians [30], which might be ad-
dressed by means of systematic training [31], decision
support, and clear accountability metrics. In future
studies, special focus must be on clinicians’ engagement
in using PROs.
Conclusions
Electronic patient reporting of symptomatic toxicities
using PRO-CTCAE was deemed feasible in prostate can-
cer patients receiving chemotherapy. Patients and oncolo-
gists stated that the electronic system was easy to use and
that the patient’s electronic reporting of PRO-CTCAE
symptomatic toxicities served to enhance communication.
The fact that electronic symptom surveillance with clin-
ician feedback using the Patient-Reported Outcomes ver-
sion of Common Terminology Criteria for Adverse Events
(PRO-CTCAE) in Danish prostate cancer patients was
shown to be feasible in this study makes us hypothesize
that the model is applicable to future research. Our future
research will examine the impact of providing patients’
PRO-CTCAE results to clinicians prior to the visit on the
quality of side effects management and resultant clinical
outcomes.
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